Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.63 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612422 | 1.00 | CAPN1 (0.63) | CAPN1ITGB1ITGA4TACR1P2RX7 | |
| SCHEMBL1613371 | 1.00 | CAPN1 (0.63) | CAPN1ITGB1ITGA4TACR1P2RX7 | |
| SCHEMBL1613331 | 0.90 | CAPN1 (0.70) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL287971 | 0.90 | CAPN1 (0.70) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL1613243 | 0.90 | CAPN1 (0.70) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL1613486 | 0.90 | CAPN1 (0.61) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL1613000 | 0.90 | CAPN1 (0.61) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL1612384 | 0.90 | CAPN1 (0.61) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL1612803 | 0.89 | CAPN1 (0.80) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL1613248 | 0.89 | CAPN1 (0.80) | CAPN1ITGB1ITGA4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252017-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-10 | — | — | US | claimed |
| EP-2516393-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2014-10-29 | — | — | EP | claimed |
| US-20110152265-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | ABBOTT GMBH & CO. KG (DE) | 2011-06-23 | — | — | US | claimed |
| US-9527811-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | disclosed |
| US-20150252017-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-10 | — | — | US | disclosed |
| US-9051304-B2 | Carboxamide compounds and their use as calpain inhibitors V | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9018206-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-09 | — | — | US | disclosed |
| EP-2516393-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20130150367-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-06-13 | — | — | US | disclosed |
| US-8283363-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT LABORATORIES (US) | 2012-10-09 | — | — | US | disclosed |
| US-20110152265-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | ABBOTT GMBH & CO. KG (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252017-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | CAPN2, CAPN1, CAPNS1 | CAPN1 2/4885ITGB1 4780/4885ITGA4 4706/4885 |
| US-20130150367-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885ITGB1 4712/4885ITGA4 4800/4885 |
| US-20110152265-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | CAPN2, CAPN1, CAPNS1 | CAPN1 2/4885ITGB1 4780/4885ITGA4 4706/4885 |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885ITGB1 4712/4885ITGA4 4800/4885 |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885ITGB1 4712/4885ITGA4 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.